InVirtuoLabs has developed an innovative protocol for drugs targeting nuclear receptors and is applying this protocol to a receptor involved in high-incidence metabolic diseases.
Founders
Gianvito Grasso
Company Description
InVirtuoLabs aims to halve development time and costs in pharmaceutical research using artificial intelligence and advanced molecular simulations. Their proprietary platform, the Next Generation Virtual Lab, uses AI and molecular modeling to identify and optimize drugs with proven precision.